细胞死亡标记物M65和M30对慢性乙型肝炎患者肝脏炎症程度的诊断价值

肝脏 ›› 2017, Vol. 22 ›› Issue (11): 991-993.

细胞死亡标记物M65和M30对慢性乙型肝炎患者肝脏炎症程度的诊断价值

韦新焕,马丽霞,范作鹏,梁珊,仇丽霞,林伟,刘义荣,胡中杰,魏红山,张晶

100069 北京首都医科大学附属北京佑安医院丙肝与中毒性肝病科(韦新焕,马丽霞,范作鹏,梁珊,仇丽霞,林伟,刘义荣,胡中杰,张晶);首都医科大学附属北京地坛医院消化内科(魏红山)

出版日期:2017-11-15 发布日期:2020-06-15
通讯作者: 张晶,Email:drzhangjing@163.com;魏红山,Email:drliver@163.com
基金资助:
艾滋病和病毒性肝炎等重大传染病防治科技重大专项(2017ZX10105005,2017ZX10302201)

The diagnostic value of cell death markers M65 and M30 for liver inflammation in chronic hepatitis B

WEI Xin-huan, MA Li-xia, FAN Zuo-peng, LIANG Shan, QIU Li-xia, LIN Wei, LIU Yi-fong, HU Zhong-jie, WEI Hong-shan, ZHANG Jing.

Beijing Youan Hospital Affliated to Capital Medical University, Beijing 100069, China

Online:2017-11-15 Published:2020-06-15
Contact: ZHANG Jing, Email: drzhangjing@163.com; Wei Hongshan, Email: drliver@163.com

摘要/Abstract

摘要： 目的明确M65和M30对慢性乙型肝炎患者肝脏炎症程度的诊断价值。方法共纳入186例未经治疗的慢性乙型肝炎患者,病理学肝脏炎症程度分为G1至G4级,肝脏纤维化程度分为S1至S4期,并在肝穿前后1周时间内采血;选择性别和年龄匹配的18例正常人作为健康对照,进行血清M65、M30检测。结果血清M65和M30水平与转氨酶有一定相关性,随着肝脏炎症程度的加重而升高,G2和cG3组的M65中位水平分别为208.3和238.8 U/L,M30中位水平为251.8和282.9 U/L,二者水平均显著高于正常人(M65:144.5 U/L;M30:208.8 U/L)和G1组(M65:199.6 U/L,M30:241.9 U/L)。多因素分析表明血清M65水平是严重肝脏炎症的独立预测指标。在S1患者中,血清M65和M30水平均随着肝脏炎症程度的加重而升高,炎症损伤较重的G2S1组的血清M65和M30中位水平为206.0 U/L、280.7 U/L,均高于G1S1组(M65:190.5 U/L,M30:241.9 U/L)。结论慢性乙型肝炎患者血清M65水平与肝组织炎症程度相关,具有一定的辅助诊断价值,其临床应用价值优于M30。

关键词: 慢性乙型肝炎, M65, M30, 肝脏炎症

Abstract: Objective To investigate the diagnostic value of cell death marker M65 and M30 for liver inflammation in patients with chronic hepatitis B (CHB).Methods A total of 186 CHB patients with liver biopsy were enrolled in the study, and the blood samples were collected within one week before and after the liver biopsy. Histopathological inflammation was graded from G1 to G4 and fibrosis was staged from S1 to S4. Eighteen health volunteers matched by sex and age were set as controls with measuring serum levels of M65 and M30.Results Serum levels of M65 and M30 increased significantly in parallel with grades of liver inflammation. The median M65 level in G2 and cG3 groups were 208.3 U/L and 238.8 U/L, and the median M30 level in G2 and cG3 groups were 251.8 U/L and 282.9 U/L, respectively, which were both significantly higher than that in control group (M65: 144.5 U/L, M30: 208.8 U/L) and G1 group (M65: 199.6 U/L, M30: 241.9 U/L). Multivariate analysis revealed that M65 was one of the independent predictors for severe liver inflammation (≥ G2). Compared with G1S1 group, G2S1 group showed higher median M65 (206.0 U/L vs 190.5 U/L ) and M30 levels (280.7 U/L vs 241.9 U/L), respectively.Conclusion Serum M65 level was positively correlated with liver inflammation grades in CHB patients, which was better than M30 in clinical application.

Key words: Chronic hepatitis B, M65, M30, Liver inflammation

韦新焕,马丽霞,范作鹏,梁珊,仇丽霞,林伟,刘义荣,胡中杰,魏红山,张晶. 细胞死亡标记物M65和M30对慢性乙型肝炎患者肝脏炎症程度的诊断价值[J]. 肝脏, 2017, 22(11): 991-993.

WEI Xin-huan, MA Li-xia, FAN Zuo-peng, LIANG Shan, QIU Li-xia, LIN Wei, LIU Yi-fong, HU Zhong-jie, WEI Hong-shan, ZHANG Jing.. The diagnostic value of cell death markers M65 and M30 for liver inflammation in chronic hepatitis B[J]. Chinese Hepatolgy, 2017, 22(11): 991-993.

参考文献

[1] Ku NO, Strnad P, Zhong BH, et al. Bishir Omary. Keratins let liver live: Mutations predispose to liver disease and crosslinking generates Mallory-Denk bodies. Hepatology, 2007, 46:1639-1649.
[2] Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res, 2004, 64:1751-1756.
[3] Leers MP, Kolgen W, Bjorklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol. 1999, 187:567-572.
[4] Joka D, Wahl K, Moeller S, et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology, 2012, 55:455-464.
[5] Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarker for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology, 2009, 50:1072-1078.
[6] Kronenberger B, Wagner M, Herrmann E, et al. Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. J Viral Hepat, 2005, 12:307-314.
[7] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版). 肝脏,2011, 16: 2-16.
[8] Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in develop-ment, immunity, and apoptotic signal transduction: lessons from knock-out mice. Immunity, 1999, 10:629-639.
[9] Abdel Haleem H, Zayed N, Abdel Hafez H, et al. Evaluation of the diagnostic value of serum and tissue apoptotic cytokeratin-18 in patients with chronic hepatitis C. Arab J Gastroenterol, 2013. 14:68-72.
[10] Papatheodoridis GV, Hadziyannis E, Tsochatzis E, et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut, 2008, 57:500-506.
[11] Bae CB, Kim SS, Ahn SJ, et al. Caspase-cleaved fragments of cytokeratin-18 as a marker of inflammatory activity in chronic hepatitis B virus infection. J Clin Virol, 2013, 58:641-646.
[12] Younossi ZM, Page S, Rafiq N, et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg, 2011, 21: 431-439.

[1]	钟大明, 蓝柏钊, 欧超兰, 陈开革, 温静, 李嘉丽, 周甦, 莫穆隆, 梁柱石. HBsAg不同载量的HBeAg阳性慢性乙型肝炎对恩替卡韦治疗应答比较[J]. 肝脏, 2020, 25(5): 505-507.
[2]	孙蔚, 杨星. 瞬时弹性成像和声脉冲辐射力成像技术诊断慢性乙型肝炎肝纤维化的价值[J]. 肝脏, 2020, 25(5): 534-535.
[3]	卢君瑶, 王登宇, 尹东林, 白玉盘, 许洁. HBV相关肝细胞癌的临床特征及危险因素分析[J]. 肝脏, 2020, 25(3): 285-287.
[4]	沈张平, 王钦君, 季沈杰. 血清miR127-3P与原发性肝癌的相关性研究[J]. 肝脏, 2020, 25(3): 302-305.
[5]	薛宏丽. HBsAg定量在慢性乙型肝炎治疗中的意义[J]. 肝脏, 2020, 25(3): 308-310.
[6]	梅栖榕, 杨丽, 沈毅. 慢性乙型肝炎患者长期服用阿德福韦酯与肾性低磷血症的相关性[J]. 肝脏, 2020, 25(3): 311-313.
[7]	孔媛媛, 魏巍, 单姗, 马红, 欧晓娟, 徐小元, 段钟平, 侯金林, 魏来, 尤红, 贾继东, 中国消除乙肝临床科研平台(CR-HepB)研究组. 乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化[J]. 肝脏, 2020, 25(2): 123-127.
[8]	江海洋, 顾生旺, 刘欢, 姬腾飞, 蒋兆荣, 吴刚, 穆小苏. 基于1 783例慢性乙型肝炎患者长期随访的结果对大幅度提高其临床治愈的思考[J]. 肝脏, 2020, 25(2): 169-171.
[9]	陈攀丽, 唐建荣, 付雪芹, 张逸强, 胡景岚, 吴小力. Hp阳性监测在慢性乙型肝炎合并消化性溃疡患者中的临床意义[J]. 肝脏, 2020, 25(2): 184-185.
[10]	黄菁, 张永臣, 虞玲. 外周血Th17相关炎性因子在慢性乙型肝炎患者接受Peg-IFNα治疗前后的变化及临床意义[J]. 肝脏, 2020, 25(2): 194-196.
[11]	马春明, 张锁才, 史罗明, 吴剑明, 周根法, 郑剑. 慢性乙型肝炎初治后转换恩替卡韦干预的耐药及疗效观察[J]. 肝脏, 2020, 25(2): 208-211.
[12]	张郴华, 钟备, 邓英, 李敏. 慢性乙型肝炎患者HBV核苷(酸)类似物预存耐药基因突变的研究[J]. 肝脏, 2020, 25(1): 39-41.
[13]	徐丹, 戴秀丽, 张晓梅, 郝咏梅. 2型糖尿病并发非酒精性脂肪性肝病患者血清趋化素、细胞角蛋白18 M30、细胞角蛋白18 M65水平及其临床意义[J]. 肝脏, 2020, 25(1): 46-49.
[14]	贾瑾堂, 施文娟, 王兆勋, 田鹏飞. 乙型肝炎慢加急性肝衰竭患者血清γ干扰素水平变化的意义[J]. 肝脏, 2020, 25(1): 61-62.
[15]	王倩倩, 胡乾坤, 张毅, 方钟, 黄晨璐, 许伟, 陈良, 黄玉仙. 抗-HBc半定量水平联合早期病毒学应答预测干扰素治疗慢性乙型肝炎的疗效[J]. 肝脏, 2019, 24(9): 1002-1006.